UroGen Pharma Ltd. (URGN) on GreekSoup https://greeksoup.ai/stocks/us/urgn/ Every dated entry in the public record on UroGen Pharma Ltd.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 UroGen Pharma Ltd.: Schedule 13G/A filed by BlackRock, Inc., 6.3% of the classhttps://greeksoup.ai/stocks/us/urgn/holders/us:URGN:schedule-13:2026-10-27:1b0bb1a60cTue, 27 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: short interest 5,607,261 shares at the 15 October 2026 settlement, 4.93 days to coverhttps://greeksoup.ai/stocks/us/urgn/short-interest/us:URGN:short-interest:2026-10-15:66250f71daThu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Form 144, Christopher Degnan plans to sell 2,202 shares worth $89,621 around 8 October 2026https://greeksoup.ai/stocks/us/urgn/planned-sales/us:URGN:planned-sale:2026-10-09:2c2bd78c1fFri, 09 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Degnan Chris (Chief Financial Officer) sold 2,202 shares at $36.69 on 8 October 2026, $80,791https://greeksoup.ai/stocks/us/urgn/insiders/us:URGN:insider:2026-10-09:761a9623b4Fri, 09 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: short interest 7,766,918 shares at the 30 September 2026 settlement, 9.91 days to coverhttps://greeksoup.ai/stocks/us/urgn/short-interest/us:URGN:short-interest:2026-09-30:4bd78da6a6Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: short interest 6,247,498 shares at the 15 September 2026 settlement, 9.16 days to coverhttps://greeksoup.ai/stocks/us/urgn/short-interest/us:URGN:short-interest:2026-09-15:e71865db73Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Form 144, Mark Schoenberg plans to sell 871 shares worth $38,402 around 8 September 2026https://greeksoup.ai/stocks/us/urgn/planned-sales/us:URGN:planned-sale:2026-09-09:f3cd865f5dWed, 09 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Form 144, Jason Smith plans to sell 1,519 shares worth $66,973 around 8 September 2026https://greeksoup.ai/stocks/us/urgn/planned-sales/us:URGN:planned-sale:2026-09-09:1f0a085141Wed, 09 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Schoenberg Mark (Chief Medical Officer) sold 871 shares at $42.92 on 8 September 2026, $37,383https://greeksoup.ai/stocks/us/urgn/insiders/us:URGN:insider:2026-09-09:1be1015d06Wed, 09 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Smith Jason Drew (General Counsel) sold 1,519 shares at $42.54 on 8 September 2026, $64,618https://greeksoup.ai/stocks/us/urgn/insiders/us:URGN:insider:2026-09-09:222b4c0b67Wed, 09 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: short interest 6,245,387 shares at the 31 August 2026 settlement, 6.79 days to coverhttps://greeksoup.ai/stocks/us/urgn/short-interest/us:URGN:short-interest:2026-08-31:33105445c2Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Schoenberg Mark (Chief Medical Officer) sold 60,677 shares at $47.05 on 20 August 2026, $2.9 millionhttps://greeksoup.ai/stocks/us/urgn/insiders/us:URGN:insider:2026-08-24:e28dbcd77cMon, 24 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/urgn/filings/us:URGN:filing:2026-08-20:5e2f7ef6e1Thu, 20 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Form 144, Schoenberg Mark plans to sell 60,677 shares worth $2.9 million around 20 August 2026https://greeksoup.ai/stocks/us/urgn/planned-sales/us:URGN:planned-sale:2026-08-20:ddd14e92b3Thu, 20 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: short interest 5,120,407 shares at the 14 August 2026 settlement, 4.80 days to coverhttps://greeksoup.ai/stocks/us/urgn/short-interest/us:URGN:short-interest:2026-08-14:4dd9cd687dFri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: Schedule 13G/A filed by The Toronto-Dominion Bank, 6.9% of the classhttps://greeksoup.ai/stocks/us/urgn/holders/us:URGN:schedule-13:2026-08-12:0f515ae2beWed, 12 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd. Q2 FY2026 results: revenue $72 million, net income -$14 millionhttps://greeksoup.ai/stocks/us/urgn/results/fy2026-q2/us:URGN:result:2026-08-05:82ee7eb29fWed, 05 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd. filed 10-Q: form 10-qhttps://greeksoup.ai/stocks/us/urgn/filings/us:URGN:filing:2026-08-05:24367907dfWed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/urgn/filings/us:URGN:filing:2026-08-05:05d965b8ebWed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> UroGen Pharma Ltd.: short interest 4,589,109 shares at the 31 July 2026 settlement, 6.64 days to coverhttps://greeksoup.ai/stocks/us/urgn/short-interest/us:URGN:short-interest:2026-07-31:120694aa79Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>